Latest News

It was a landmark day they never expected to celebrate. Tristan Hall’s family were told he would not reach his first birthday – so they were delighted when he not only surpassed that but is now the proud owner of his first tooth. The brave tot celebrated his birthday in...
WASHINGTON DC – Gene-editing technologies are progressing fast, and there are now more than 100 ongoing trials for new therapies and diagnostics based on CRISPR-Cas, zinc finger nucleases, TALENS, and base editors. While most of these trials are evaluating ex vivo gene-edited cell-based therapies for cancers and genetic blood disorders,...
New York, NY – Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets, according to a study by Weill Cornell Medicine investigators. They have conducted the first whole genome sequencing analysis of male breast cancer, which looked at the complete DNA landscape of...
New York, NY – Weill Cornell Medicine researchers and the TB Drug Accelerator have received two grants totaling $6.8 million from the Bill & Melinda Gates Foundation to study tuberculosis (TB) drug development. This effort will expediate finding new drug targets within the bacteria and identifying new lead compounds, two...
New York, NY – Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine in New York and GHESKIO Centers in Haiti. Second-line medications are those that are given when...
New York, NY – Lung tumors called adenocarcinomas sometimes respond to initially effective treatments by transforming into a much more aggressive small cell lung cancer (SCLC) that spreads rapidly and has few options for treatment. Researchers at Weill Cornell Medicine have developed a mouse model that illuminates this problematic process,...